Composition comprising a vasoconstrictor for preventing peripheral neuropathies
A topical hydrogel with brimonidine tartrate addresses the inadequacies of current treatments by preventing chemotherapy-induced neuropathies through vasoconstriction, providing effective prevention and treatment with improved tolerance and safety.
WO2026125318A1 Publication Date: 2026-06-18TARIAN PHARMA
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- TARIAN PHARMA
- Filing Date
- 2025-12-09
- Publication Date
- 2026-06-18
AI Technical Summary
⚠Technical Problem
Current treatments for chemotherapy-induced peripheral neuropathies are inadequate, with no effective pharmacological interventions and existing methods like cooling gloves having poor tolerance and limited efficacy.
⚗Method used
A topical composition containing an adrenergic agonist, such as brimonidine tartrate, is developed for use in a hydrogel form to prevent chemotherapy-induced peripheral neuropathies by inducing vasoconstriction and reducing chemotherapy dose at the treatment site.
🎯Benefits of technology
The composition effectively prevents and treats peripheral neuropathies by reducing chemotherapy exposure at the site, offering better tolerance and broader application than cooling methods, with minimal systemic absorption and adverse effects.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 1 Figure 2 
Figure 3
Abstract
The invention relates to a composition in a form suitable for topical administration, comprising, in a physiologically acceptable medium, a vasoconstrictor. The invention is characterized in that the composition comprises a vasoconstrictor selected from adrenergic agonists, for use in the prevention and / or treatment of peripheral neuropathies regardless of their cause, and more particularly those induced by chemotherapy during the treatment of cancer.
Need to check novelty before this filing date? Find Prior Art